Daniel P. Nguyen

Daniel P. Nguyen

Auto-generated profile, based on publicly available information

Daniel P. Nguyen

University of Berne

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in European Urology
Verified
Journal Article
Closed access
DNDaniel P. Nguyen
Daniel P. Nguyen
BABashir Al Hussein Al Awamlh
Bashir Al Hussein Al Awamlh
XWXian Wu
Xian Wu
POPadraic O’mAlley
Padraic O’mAlley
IIIgor M. Inoyatov
Igor M. Inoyatov
DSDouglas S. Scherr
Douglas S. Scherr

1 June 2016 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
DNDaniel P. Nguyen
Daniel P. Nguyen
EVEmily A. Vertosick
Emily A. Vertosick
RCRenato B. Corradi
Renato B. Corradi
TVToni Vilaseca
Toni Vilaseca
NBNicole E. Benfante
Nicole E. Benfante
PRPaul Russo
Paul Russo

1 November 2016 in Journal of Urology
Verified
Journal Article
Closed access
DNDaniel P. Nguyen
Daniel P. Nguyen
BABashir Al Hussein Al Awamlh
Bashir Al Hussein Al Awamlh
POPadraic O’malley
Padraic O’malley
FKFarehin Khan
Farehin Khan
PLPatrick J.E. Lewicki
Patrick J.E. Lewicki
DSDouglas S. Scherr
Douglas S. Scherr
Peritoneal carcinomatosis and extrapelvic lymph node metastases can be seen following robot-assisted radical cystectomy. In an attempt to identify predictors of these atypical metastases we report a detailed analysis of patients treated with robot-assisted radical cystectomy in whom recurrences developed. A total of 310 patients underwent robot-assisted radical cystectomy for bladder cancer from 2001 to 2015. Descriptive statistics were used to compare baseline variables between patients without recurrence and those with local, distant or atypical recurrence. Univariate and multivariable regression models were used to assess the effect of variables on oncologic outcomes including recurrence location. At a median followup of 24 months (IQR 14-51) 81 patients had recurrence. On multivariable analysis tumor classification, lymphovascular invasion, estimated glomerular filtration rate less than 60 ml/minute/1.73 m2 and perioperative blood transfusion were significantly associated with any recurrence. Specific analyses showed that tumor and nodal classification, lymphovascular invasion and positive surgical margins were associated with all 3 recurrence locations (all p <0.05). Previous abdominal surgery was protective against atypical recurrences (HR 0.36, 95% CI 0.13-0.95, p = 0.04). Estimated glomerular filtration rate less than 60 ml/minute/1.73 m2 and perioperative blood transfusion conferred a higher risk of distant or atypical recurrence but not of local recurrence (all p <0.05). Operative time and previous pelvic radiotherapy were not associated with any recurrence locations. Predictors of distant recurrences, peritoneal carcinomatosis and extrapelvic lymph node metastases after robot-assisted radical cystectomy did not significantly differ and were mainly dictated by pathological tumor characteristics. Results suggest that the risk of atypical recurrence is chiefly influenced by tumor biology rather than surgical aspects.

1 November 2016 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
DNDaniel P. Nguyen
Daniel P. Nguyen
PXPeter L. Xiong
Peter L. Xiong
HLHe Liu
He Liu
SPSamuel Pan
Samuel Pan
WLWilhem Leconet
Wilhem Leconet
NBNeil H. Bander
Neil H. Bander
Angiogenesis is critical for tumor growth and survival and involves interactions between cancer and endothelial cells. Prostate-specific membrane antigen (PSMA/FOLH1) is expressed in the neovasculature of several types of cancer. However, the study of neovascular PSMA expression has been impeded as human umbilical vein endothelial cell (HUVEC) cultures are PSMA-negative and both tumor xenografts and patient-derived xenograft (PDX) models are not known to express PSMA in their vasculature. Therefore, PSMA expression was examined in HUVECs, in vitro and in vivo, and we tested the hypothesis that cancer cell–HUVEC crosstalk could induce the expression of PSMA in HUVECs. Interestingly, conditioned media from several cancer cell lines induced PSMA expression in HUVECs, in vitro, and these lines induced PSMA, in vivo, in a HUVEC coimplantation mouse model. Furthermore, HUVECs in which PSMA expression was induced were able to internalize J591, a mAb that recognizes an extracellular epitope of PSMA as well as nanoparticles bearing a PSMA-binding ligand/inhibitor. These findings offer new avenues to study the molecular mechanism responsible for tumor cell induction of PSMA in neovasculature as well as the biological role of PSMA in neovasculature. Finally, these data suggest that PSMA-targeted therapies could synergize with antiangiogenic and/or other antitumor agents and provide a promising model system to test therapeutic modalities that target PSMA in these settings.Implications: Cancer cells are able to induce PSMA expression in HUVECs, in vitro and in vivo, allowing internalization of PSMA-specific mAbs and nanoparticles bearing a PSMA-binding ligand/inhibitor. Mol Cancer Res; 14(11); 1045–53. ©2016 AACR.

20 November 2014 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
DNDaniel P. Nguyen
Daniel P. Nguyen
BABashir Al Hussein Al Awamlh
Bashir Al Hussein Al Awamlh
EOE. Charles Osterberg
E. Charles Osterberg
JCJames Chrystal
James Chrystal
TFThomas Flynn
Thomas Flynn
DSDouglas S. Scherr
Douglas S. Scherr

17 September 2017 in BJU International
Verified
Journal Article
Closed access
PDF file
lydia maderthanerlydia maderthaner
lydia maderthaner
MFMarc A. Furrer
Marc A. Furrer
USUrs E. Studer
Urs E. Studer
FBFiona C. Burkhard
Fiona C. Burkhard
GTGeorge N. Thalmann
George N. Thalmann
DNDaniel P. Nguyen
Daniel P. Nguyen